Skip to main content
Clinical Trials/NCT02928471
NCT02928471
Completed
Not Applicable

Multi-parametric Imaging of the Knee in Obese Patients With Knee Osteoarthritis Following a Significant Weight Loss, Investigating the Impact on Inflammation (A Substudy to "Effect of Liraglutide on Body Weight and Pain in Overweight or Obese Patients With Knee Osteoarthritis: A Randomised, Double Blind, Placebo-controlled, Parallel Group, Single-centre Trial" (NCT02905864)

Henrik Gudbergsen1 site in 1 country200 target enrollmentStarted: November 2016Last updated:

Overview

Phase
Not Applicable
Status
Completed
Sponsor
Henrik Gudbergsen
Enrollment
200
Locations
1
Primary Endpoint
Change in the degree of inflammation in the knee-joint (DCE-MRI)

Overview

Brief Summary

This is a substudy to a randomised trial investigating the effect of liraglutide on body weight and pain in overweight or obese patients with knee osteoarthritis (NCT02905864). In the parent trial, patients will be subjected to an 8-week diet intervention phase including a low-calorie diet and dietetic counseling, after which. Patients will be randomised to receive either liraglutide 3 mg or liraglutide 3 mg placebo as an add-on to dietetic guidance on re-introducing regular foods and a focus on continued motivation to engage in a healthy lifestyle.

This substudy aims to investigate any changes in MRI associated with the initial 8-week weight loss intervention, and the value of CT scans in predicting the effect of weight loss.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to 74 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Same as parent trial (NCT02905864)
  • Further Exclusion Criteria
  • Same as parent trial (NCT02905864)
  • Usual exclusion criteria for MRI (i.e. pacemakers etc.)

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Change in the degree of inflammation in the knee-joint (DCE-MRI)

Time Frame: Week -8 to 0

Change will be assessed via a dynamic contrast enhanced MRI evaluation of corpus hoffa (Ballegaard C et al. and Riis RG et al.)

Secondary Outcomes

  • Change in the degree of inflammation in the knee-joint (MRI)(Week -8 to 0)
  • Change in cartilage composition(Week -8 to 0)
  • Change in the degree of inflammation in the knee-joint (CE-MRI)(Week -8 to 0)
  • Prediction of clinical symptoms (KOOS pain) by the level of crystal deposition on dual-energy CT at week 0(Week 0)
  • Change in bone marrow lesions (BML)(Week -8 to 0)

Investigators

Sponsor
Henrik Gudbergsen
Sponsor Class
Other
Responsible Party
Sponsor Investigator
Principal Investigator

Henrik Gudbergsen

MD, PhD

Parker Research Institute

Study Sites (1)

Loading locations...

Similar Trials